期刊文献+

新型抗ErbB2、抗CD16三价双特异性抗体的构建及功能鉴定

Construction and functional identification of a novel trivalent anti-ErbB2/anti-CD16 bispecific antibody
下载PDF
导出
摘要 目的构建一种新型三价抗ErbB2、抗CD16 BsAb。方法构建重组载体pET22b(+)/BsAb;转化大肠杆菌BL21(DE3),获得重组蛋白的表达,通过包涵体复性纯化蛋白。应用悬浮培养系统扩增稳定表达抗人CD16 scFv-Fc融合蛋白的CHO细胞株(CG5细胞)和稳定表达抗人ErbB2 scFv-Fc融合蛋白的CHO细胞株(HG2细胞),通过rProtein A Sepharose Fast Flow亲和层析柱纯化融合蛋白,应用流式细胞术分析BsAb的结合能力。结果该BsAb可在大肠杆菌BL21(DE3)中以包涵体形式高效表达,通过对重组蛋白的复性可获得高纯度的蛋白;复性后的BsAb具有与其亲本抗体相似性的结合靶抗原的能力。结论新型三价抗ErbB2、抗CD16 BsAb能与高表达ErbB2的乳腺癌细胞系SKBR3细胞高亲和力结合和表达CD16的人外周血单个核细胞低亲和力结合。 Objective To construct a novel trivalent anti-ErbB2/CD16 bispecific antibody.Methods The recombinant plasmid pET22b(+)/BsAb was constructed.The recombinant protein was expressed in E.coli BL21 strain(DE3) and purified by refolding.By using Spinner System,CG 5 cells,CHO cells stably expressing anti-CD16 scFv-Fc fusion protein and HG 2 cells,CHO cells stably expressing anti-ErbB2 scFv-Fc fusion protein were expanded.The fusion proteins were purified over rProtein A Sepharose Fast Flow Column.The binding activity of the BsAb was analyzed by flow cytometry.Results The BsAb was efficiently expressed in E.coli BL21 strain(DE3) as inclusion bodies.High purity of recombinant protein could be obtained by refolding.The BsAb possessed the capability of binding to the target antigens as its parental antibodies. Conclusion The novel BsAb was able to bind human breast cancer cell line SK-BR-3 highly expressing ErbB2 and human peripheral blood mononuclear cells expressing CD16.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2008年第5期489-495,共7页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 国家基础研究发展规划项目“973”资助项目(No.2006CB504305) 国家高技术研究与发展项目“863”资助项目(No.2006AA02A245) 国家自然科学基金资助项目(No.30571716和No.30771981)
关键词 双特异性抗体 ERBB2 CD16 肿瘤免疫治疗 bispecific antibody ErbB2 CD16 tumor immunotherapy
  • 相关文献

参考文献13

  • 1Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies [J]. Am J Med Sci, 2002, 324(1) :14-30.
  • 2Carter P. Improving the efficacy of antibody-based cancer therapies [J]. Nat Rev Cancer, 2001, 1(2) :118-129.
  • 3Chames P, Baty D. Antibody engineering and its applications in tumor targeting and intracellular immunization [J]. FEMS Microbiol Lett, 2000, 189(1):1-8.
  • 4Valone FH, Kaufman PA, Guyre PM, et al. Phase Ⅰa/Ⅰb trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER- 2/neu [J]. J Clin Oncol, 1995, 13:2281-2292.
  • 5Weiner LM, Clark JI, Ring DB, et al. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RⅢ [J]. J Hematother, 1995, 4(5):453-456.
  • 6de Leij L, Molema G, Helfrich W, et al. Bispecific antibodies for treatment of cancer in experimental animal models and man [J]. Adv Drug Deliv Rev, 1998, 31(1-2) :105-129.
  • 7Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy [J]. Curr Opin Immunol, 1999, 11(5) :558-562.
  • 8Clynes R, Takechi Y, Moroi Y, et al. Fc receptors are required in passive and active immunity to melanoma [J]. Proc Natl Acad Sci USA, 1998, 95(2) :652-656.
  • 9Feng J, Xie Z, Guo N, et al. Design and assembly of antiCD16 ScFv antibody with two different linker peptides [J]. J Immunol Methods, 2003, 282(1-2) :33-34.
  • 10解志刚,郭宁,施明,冯建男,于鸣,孙瑛勋,沈倍奋.抗人P185^(erbB2)的scFv-Fc融合蛋白的表达及免疫功能分析[J].生物化学与生物物理学报,2003,35(4):371-374. 被引量:3

二级参考文献9

  • 1Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 1998, 34(6): 791 -808.
  • 2Lohrisch C, Piccart M. An overview of HER2. Semin Oncol,2001,28(6 Suppl18): 3 - 11.
  • 3Wang B, Chen YB, Ayalon O, Bender J, Garen A. Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proc Natl Acad Sci USA, 1999, 96(4): 1627 - 1632.
  • 4TongYG XuJ LiuGQ ZhangYG ChenWR LiuSL WangHT.Cloning of human IgG Fc cDNA and expression of whole human anti—HbsAg antibody in CHO cells[J].Acta Biochimica et Biophysica Sinica(生物化学与生物物理学报:英文版),2000,32(4):392-396.
  • 5Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning:A Laboratory Manual, 2nd ed. Beijing : Science Press, 1989,870 - 898.
  • 6Bator JM, Reading CL. Measurement of antibody affinity for cell surface antigens using an enzyme-linked immunosorbent assay. J Immunol Methods, 1989, 125(1-2): 167 - 176.
  • 7Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR,Adams GP, Weiner LM et al. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods, 2001,251(1-2):123 -135.
  • 8Wu AM, Tan G J, Sherman MA, Clarke P, Olafsen T, Forman S J, Raubitschek AA. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng, 2001, 14(12): 1025 -1033.
  • 9解志刚,郭 宁,施 明,冯健男,孙瑛勋,于 鸣,沈倍奋.抗人CD16单克隆抗体可变区基因的克隆和表达[J].免疫学杂志,2002,18(3):183-186. 被引量:5

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部